BioMarin Pharmaceutical retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $-0.320B, a 50.21% decline year-over-year.
BioMarin Pharmaceutical retained earnings (accumulated deficit) for 2023 were $-0.622B, a 21.24% decline from 2022.
BioMarin Pharmaceutical retained earnings (accumulated deficit) for 2022 were $-0.789B, a 15.21% decline from 2021.
BioMarin Pharmaceutical retained earnings (accumulated deficit) for 2021 were $-0.931B, a 8.03% increase from 2020.